Drug Profile
Research programme: antibody-drug conjugates - Pfizer/Seagen
Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer; Seattle Genetics
- Developer Pfizer; Seagen
- Class Antibodies; Drug conjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer